EverHint Lens - Soleno Therapeutics, Inc. ($SLNO) - Yahoo Finance Top Gainer (+32%) Stock Analysis - April 06, 2026

Analysis Date: 2026-04-06
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

Executive Summary

Soleno Therapeutics, Inc. is currently trading at $52.20 (🟢 +32.19% today) with a market capitalization of $2.80B.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc.

Price & Valuation

Current Price: $52.20 (at 11:41 AM ET)
Current Volume: 44.5M
Day Range: $52.15 - $52.34
52-Week Range: $29.43 - $90.32
P/E Ratio: 132.92

DCF Valuation: Undervalued

• Intrinsic Value (Unlevered DCF): $165.78
• Current Price: $52.20
• Discount/Premium: +217.6%

Levered DCF: $88.13 (+68.8%)

⚠️ High divergence between levered and unlevered DCF
⚠️ DCF shows extreme valuation gap (>100%)

DCF analysis suggests the stock may be trading at a 217.6% discount to its intrinsic value.

DCF values calculated as of 2026-04-06. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.

Market Context

Major Indices:

• S&P 500: $6590.77 (🟢 +0.12%)
• NASDAQ Composite: $21938.22 (🟢 +0.27%)
• Dow Jones Industrial Average: $46536.11 (🟢 +0.07%)

Peer Comparison

Peer comparison (11 companies):

• SLNO - Soleno Therapeutics, Inc. ($52.20, +32.2%, $2.80B) ← Current
• PRAX - Praxis Precision Medicines, Inc. ($314.75, +1.4%, $6.65B)
• CELC - Celcuity Inc. ($114.00, +1.2%, $5.51B)
• CNTA - Centessa Pharmaceuticals plc ($39.73, +0.1%, $5.34B)
• MIRM - Mirum Pharmaceuticals, Inc. ($96.15, +2.1%, $4.83B)
• APGE - Apogee Therapeutics, Inc. ($83.78, -0.7%, $4.69B)
• XENE - Xenon Pharmaceuticals Inc. ($56.73, -0.2%, $4.48B)
• VKTX - Viking Therapeutics, Inc. ($34.85, +0.1%, $4.03B)
• DYN - Dyne Therapeutics, Inc. ($18.73, -0.6%, $3.09B)
• AAPG - Ascentage Pharma Group International ($27.38, +0.2%, $2.54B)
• RARE - Ultragenyx Pharmaceutical Inc. ($22.74, +1.3%, $2.20B)

Financial Performance

Latest Quarter (2025-12-31):

• Revenue: $91.73M
• Net Income: $43.36M
• EPS: $0.96
• Revenue Growth (QoQ): +38.9%

Stock Split History

SLNO has executed 2 stock split(s) historically

• 2022-08-26: 1-for-15 split
• 2017-10-06: 1-for-5 split

Cumulative Split Factor: 0x (1 share in 1987 = 0 shares today)

Most recent split: 1-for-15 on 2022-08-26

Earnings Calendar

Next Earnings Report: 2026-05-06 (Before Market Open)

• EPS Estimate: $0.66
• Revenue Estimate: $0.09B

Most Recent Report: 2026-02-25

• EPS: $0.80 (Est: $0.64) ✓ Beat
• Revenue: $0.09B

Historical Data: 53 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $101.20 (+93.9% upside)
• Range: $60.00 - $125.00
• Median: $107.00

Next Quarter Estimates (2028-06-30):

• Revenue: $91.73M
• EPS: $7.33

Analyst Consensus

Overall Rating: Buy

Rating Distribution (44 total ratings):

• 🟢 Buy/Outperform: 44 (100.0%)
• ⚪ Hold/Neutral: 0 (0.0%)
• 🔴 Sell/Underperform: 0 (0.0%)

Recent Analyst Actions:

• Goldman Sachs (2025-10-07): Initiate Buy
• Cowen & Co. (2025-06-23): Initiate Buy
• H.C. Wainwright (2026-03-04): Maintain Buy
• Wells Fargo (2026-01-20): Maintain Overweight
• H.C. Wainwright (2026-01-20): Maintain Buy

Consensus based on 44 analyst ratings from major financial institutions

Insider Activity

Recent Transactions (Last 10):

• Buys: 3
• Sells: 6

Notable Transactions:

• 2026-03-27: Manning Meredith - Sell (Sale, 4,864 shares @ $30.04)
• 2026-03-27: Manning Meredith - Sell (Sale, 2,100 shares @ $31.04)
• 2026-03-27: Manning Meredith - Sell (Sale, 558 shares @ $31.72)

News Sentiment Analysis

AI Analysis (based on 30 recent articles):

Soleno Therapeutics faces a mix of major positive news with Neurocrine Biosciences' $2.9 billion acquisition announcement, validating its FDA-approved hyperphagia drug. However, coverage is dominated by numerous securities class action lawsuits alleging fraud over prior drug launch disruptions and share drops. Shareholder alerts also probe the deal's fairness to public investors.

Key Themes:

• Acquisition by Neurocrine
• Securities Fraud Lawsuits
• Shareholder Investigations

Sentiment: Neutral (88% confidence)

Recent News

5 most recent articles covering SLNO:

• Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.'s Transaction with Neurocrine is Fair to Public Shareholders (prnewswire.com, 2026-04-06) — Read more
• Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal (proactiveinvestors.com, 2026-04-06) — Read more
• SLNO Stock Alert: Halper Sadeh LLC is Investigating Whether Soleno Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders (businesswire.com, 2026-04-06) — Read more
• Soleno Therapeutics (SLNO) Faces Securities Class Action Amid Hyperphagia Drug Launch Disruptions -- Hagens Berman (globenewswire.com, 2026-04-06) — Read more
• Neurocrine to Buy Soleno for $2.9 Billion (wsj.com, 2026-04-06) — Read more

Full news analysis based on 30 recent articles

Generated by Everhint Lens - Quantitative Stock Analysis
Last updated: 2026-04-06 08:41:56 AM PDT

Disclaimer: This is not investment advice. Always do your own research before making investment decisions.